Michael Wolf
About Michael Wolf
Michael Wolf serves as the Country Medical Lead for Germany at Travere Therapeutics, a position he has held since 2019. With extensive experience in the pharmaceutical industry, he has previously worked at companies such as Ablynx, Alexion Pharmaceuticals, and Pfizer, contributing to product launches and stakeholder engagement in various therapeutic areas.
Work at Travere Therapeutics
Michael Wolf serves as the Country Medical Lead for Germany at Travere Therapeutics. He has held this position since 2019, contributing to the company's initiatives in the German healthcare market. His role involves building relationships with healthcare professionals, payers, and patient advocacy groups to facilitate product launches. He integrates new digital tools and applies design thinking in launch strategies and life cycle management.
Previous Experience in the Pharmaceutical Industry
Prior to his current role, Michael Wolf worked at Ablynx as the Medical Lead for Germany from 2017 to 2019. He also served as a Key Account Manager at Alexion Pharmaceuticals from 2012 to 2014. His experience includes a position as Medical Science Liaison for Nephrology at Alexion Pharmaceuticals from 2014 to 2017, and as a PV Specialist at Pfizer from 2009 to 2011. Additionally, he worked as a Sales Representative at Encysive Pharmaceuticals and Schwarz Pharma.
Education and Expertise
Michael Wolf has a strong educational background in health economics and biotechnology. He studied at Hochschule Mannheim, earning a Dipl.Ing in Biotechnology from 1994 to 2000. He later obtained a Master's degree in Clinical Research Management and Health Economics from Wissenschaftliche Hochschule Lahr between 2010 and 2014. Additionally, he studied Market Access Management at EBS Universität für Wirtschaft und Recht from 2019 to 2020 and achieved the title of Health Economist from the same institution from 2018 to 2019.
Achievements in Product Launches
Michael Wolf has successfully led product launches in orphan diseases, including pulmonary arterial hypertension (PAH), atypical hemolytic uremic syndrome (aHUS), thrombotic thrombocytopenic purpura (TTP), focal segmental glomerulosclerosis (FGSG), and immunoglobulin A nephropathy (IgAN). He often served as the first hire in Germany for these initiatives. His contributions include boosting clinical trial recruitment and supporting the development of Health Technology Assessment (HTA) dossiers.
Role in Stakeholder Engagement
In his various roles, Michael Wolf has played a crucial part in building stakeholder networks that include healthcare professionals, payers, and patient advocacy groups. His efforts have facilitated product launches and strengthened relationships within the healthcare ecosystem. He has also been integral to cross-functional teams that develop market-tailored launch strategies.